Gynica

A biotech company developing cannabinoid-based solutions for women's health, focusing on endometriosis.

Health Tech & Life Sciences
Active
Seed Tel Aviv, Israel Founded 2017
Last updated 2026-07-26
Total raised
$4.0M
Last: Undisclosed Round 2021-06
Stage
Seed
Founded
2017
Headcount
5
HQ
Tel Aviv, Israel
Sector
Health Tech & Life Sciences

About

Gynica is an Israeli biotech company focused on improving the lives of women suffering from endometriosis and other gynecological conditions by developing safe, effective, non-hormonal, intra-vaginal therapeutic solutions. The company utilizes its proprietary IntraVag© microencapsulation technology for controlled-release of active pharmaceutical ingredients (APIs) directly to the vaginal cavity, aiming for maximum efficacy with minimal systemic absorption and side effects. Gynica's research bridges the knowledge gap in cannabinoids and women's health, with studies suggesting a link between endometriosis and endocannabinoid deficiency. Gynica is owned by Asana Bio Group, a holding company specializing in life sciences innovations.

Funding history · 2 rounds · $4.0M total

2021-05
Seed $2.0M
2019-06
Pre-Seed $2.0M

Headcount over time

From 1 (2019-06) to 9 (2024-08) · +8 (+800%) · 19 points · source: Finder history + radar grounding
110 2019-06 2024-08

Q&A

What is Gynica's primary focus?
Gynica is an Israeli biotech company focused on developing cannabinoid-based solutions for women's health, specifically targeting endometriosis and other gynecological conditions.
What is Gynica's proprietary technology?
Gynica utilizes its proprietary IntraVag© microencapsulation technology for controlled-release of active pharmaceutical ingredients (APIs) directly to the vaginal cavity.
What is the current employee count for Gynica?
Gynica currently has 5 employees, falling within the 1-10 employee bucket.
What is the total amount of funding Gynica has raised to date?
Gynica has raised a total of $4,000,000 USD.
When did Gynica announce its first-in-human clinical trial for its IntraVag© treatment for endometriosis?
Gynica announced its first-in-human clinical trial for its novel IntraVag© treatment for endometriosis on March 14, 2024.
What is Gynica's primary sector?
Gynica's primary sector is Health Tech & Life Sciences.
Who are the co-founders of Gynica?
The co-founders of Gynica are Yotam Hod, who also serves as CEO, and Dor Hershkovitz.

Team · 2

Yotam Hod
Founder · CEO & Co-Founder
Dor Hershkovitz
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryDrugs Discovery & Development
Technologies
Materials & SubstancesRaw MaterialsBiologicalsHerbalsMolecules
Target customers
Healthcare & Life SciencesMedical Devices IndustryMedical ProductsLife SciencesPharmaceuticalsBiotechnologyConsumersDemographics & FamilyWomen
Business model
B2B

Highlights

1 PatentsVerified

Tags

biopharmaceuticalwomendrug-developmentcannabismedical-devicesdrug-discoverydrug-designgynecologywomen-healthmedical-technologiestherapeuticsbiotechnologypharmaceuticalsdrug-deliveryfemtechmedical-cannabispharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitegynica.com/
LinkedInlinkedin.com/company/13974274

Identifiers & details

Legal nameGYNICA ABG LTD
Founded2017
Employees (exact)5

Radar intelligence

Patents

EPO1

Web history (Wayback)

Domaingynica.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516107174
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2019-11-18
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)yes
Last annual report2025
Active charges / liens0
Registry events3 — violation (1), shares_capital (1), annual_report (1)
Registered addressסטימצקי 10 תל אביב - יפו

Recent registry events

DateEvent
2026-06-25עדכון הפרה
2025-12-03הקצאת מניות
2026-06-01דו~ח שנתי-עדכון כתובת